Mirtazapine added to a low-FODMAP diet for irritable bowel syndrome with diarrhea
Tests mirtazapine plus a low-FODMAP diet in adults with diarrhea-type irritable bowel syndrome.
Key facts
- Who runs it
- Mayo Clinic
- Where
- Jacksonville, United StatesSee the site
- Trial code
- Registry title
- Novel Pilot Study to Treat Symptoms of IBS With Diarrhea Using Combination Therapy of a Low-FODMAP Diet and a Neuromodulator
- Status
- Recruiting
- Phase
- Early phase 1
- People taking part
- 20 people, planned
- Started
- 19 Dec 2024
- Expected to end
- 19 Dec 2026
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Mirtazapine
- Placebo
- Record updated
- 18 December 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with irritable bowel syndrome with diarrhea (IBS-D). It tests mirtazapine or a placebo pill together with a low-FODMAP diet.
- Age
- 18 to 70 years
- Sex
- All sexes
- Disease stage
- IBS with diarrhea under the Rome IV criteria, with a score above 175 on the IBS-SSS symptom questionnaire.
- Earlier treatment
- People who tried a low FODMAP diet or mirtazapine before and it did not help cannot join.
- Biomarker or test result
- People who can become pregnant need a negative urine pregnancy test before they start.
Main reasons for not taking part
- Celiac disease, small intestinal bacterial overgrowth, inflammatory bowel disease or microscopic colitis
- Ongoing significant anxiety or depression
- A known side effect from mirtazapine in the past
- Active alcohol or drug abuse
- Being pregnant
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- Participants must meet all of the inclusion criteria to participate in this study:; Adults (ages 18-70); Score of >175 on the IBS-SSS questionnaire; Must meet Rome IV criteria for IBS-D; If subject is of reproductive capability a negative urine pregnancy test must be available prior to entering the study; Ability to understand study procedures and to comply with them for the entire length of the study
Who cannot take part
- All candidates meeting any of the below exclusion criteria at baseline will be excluded from study participation:; Score of < 175 on the IBS-SSS; Prior diagnoses of: known celiac disease, small intestinal bacterial overgrowth, inflammatory bowel disease, or microscopic colitis; Ongoing significant anxiety or depression; A history of a known side effect to mirtazapine; Prior treatment with a low FODMAP diet or mirtazapine without clinical benefit; Active alcohol or drug abuse; Inability to read or understand the consent form; Any other medical or psychological reason that would prevent active participation in a research study; Pregnant females
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Where in United States
- Mayo ClinicJacksonville, United StatesContact: Jessica C Petrov, M.D.Taking people
About the trial
What the trial wants to find out
The purpose of this research is to study the added benefit of treating IBS symptoms with a medication called mirtazapine in treating IBS symptoms when paired with a low-FODMAP diet compared to a low-FODMAP diet alone. FODMAP stands for fermentable oligosaccharides, disaccharides, monosaccharides, and polyols. These are short-chain carbohydrates that can cause digestive distress in some people.
Read full original descriptionShow less
You have been asked to take part in this research because you have symptoms of diarrhea-predominant irritable bowel syndrome that may respond to treatment with a combination of a medication called mirtazapine and a low-FODMAP diet.
The 2 groups in the trial
- Mirtazapine GroupTreatment being tested
Subjects will present at Mayo Clinic through a doctor's appointment and a diagnosis of irritable bowel syndrome will be receiving mirtazapine by pill form.
Treatment: Mirtazapine
- Placebo GroupPlacebo, for comparison
Subjects will present at Mayo Clinic through a doctor's appointment and a diagnosis of irritable bowel syndrome will be receiving placebo by pill form.
Treatment: Placebo
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Novel Pilot Study to Treat Symptoms of IBS With Diarrhea Using Combination Therapy of a Low-FODMAP Diet and a Neuromodulator
- Plain-language title
- Mirtazapine added to a low-FODMAP diet for irritable bowel syndrome with diarrheaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Fit questions
- Built from NCT06684470, who can take part
- Record updated
- 18 December 2025